NCT06726031

Brief Summary

Compared to transfemoral access, transradial access is a safe and effective method for coronary interventions, associated with lower rates of vascular complications, including major bleeding. Additionally, it facilitates early ambulation and reduces post-procedural hospital stays. As a result, current guidelines now recommend transradial access as the preferred approach for coronary interventional procedures. However, the most commonly recognized limitation of this method is radial artery spasm (RAS). The radial artery is more susceptible to spasm than other peripheral arteries due to its thicker muscular layer and the predominance of alpha-adrenergic receptors. RAS can sometimes limit the advantages of transradial access, prolong procedural duration, or even lead to procedural failure and termination. Consequently, the prevention of potential causes of RAS has garnered significant interest. The reported incidence of RAS ranges between 7.8% and 25%. These rates are notably high for diagnostic procedures, underscoring the importance of identifying and addressing risk factors before the intervention. The literature identifies several risk factors for RAS, including female sex, advanced age, smaller radial artery diameter, and the number of interventions performed. Cardiac procedures frequently induce pain and anxiety in patients. The prevalence of anxiety disorders among patients with cardiovascular diseases can reach up to 15%, with cardiac procedures exacerbating these conditions, resulting in anxiety prevalence rates as high as 72%. Given the limitations of pharmacological approaches in managing pain and anxiety, innovative digital solutions such as virtual reality (VR) have been proposed. However, VR was not found to have a statistically significant effect on pain levels. The literature review revealed that, based on the current understanding, no prior studies have investigated the impact of VR headset use on anxiety-induced vasospasm in patients undergoing transradial coronary angiography. Therefore, the study aimed to explore whether VR applications could influence the successful completion of this widely performed procedure worldwide.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 29, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 10, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

December 10, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

December 10, 2024

Status Verified

December 1, 2024

Enrollment Period

3 months

First QC Date

November 29, 2024

Last Update Submit

December 8, 2024

Conditions

Keywords

radial artery spasmvirtual realityanxiety

Outcome Measures

Primary Outcomes (1)

  • the Visual Analog Scale (VAS)

    Visual Analog Scale (VAS) is used to convert certain non-quantifiable values into numerical data. A 100-mm line is marked with two extreme descriptions of the parameter being evaluated at each end. Patients are asked to indicate their current state on the line by drawing a mark, placing a dot, or pointing to a specific location. For example, in the case of pain, one end of the line might read "no pain at all," and the other end "worst imaginable pain." The patient marks the point on the line that best represents their current pain level. The distance from the "no pain" end to the point marked by the patient represents the intensity of the pain they are experiencing. The length of the line between these two points serves as a measure of the patient's subjective experience.

    day 1

Secondary Outcomes (1)

  • the State-Trait Anxiety Inventory (STAI)

    day 1

Study Arms (2)

control group

NO INTERVENTION

Participants in this group will not undergo VR glasses application during transradial coronary angiography.

VR Glass Group

ACTIVE COMPARATOR

Participants in this group will use VR glasses during transradial coronary angiography. With the help of VR glasses, patients will be shown visuals based on nature and listen to calming sounds.

Device: wearing VR glass

Interventions

The intervention is the application of VR headsets during the procedure for patients who were previously indicated for transradial coronary angiography and were randomized to the VR headset group.

VR Glass Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Indicated for coronary angiography via the transradial approach for reasons other than Acute Coronary Syndrome.
  • Patients with no prior history of coronary angiography
  • Patients aged 18 years and older
  • Patients who are conscious, oriented, cooperative, and able to read and understand Turkish.
  • Patients without any physical issues that would prevent the use of virtual reality glasses.
  • Patients with no known malignancy, neuropsychiatric disorders, or diagnosed anxiety disorders.
  • Patients who agree to participate in the study and sign the "Informed Consent Form" will be included.

You may not qualify if:

  • Patients indicated for coronary angiography due to Acute Coronary Syndrome,
  • Patients undergoing coronary angiography via an approach other than the transradial route,
  • Patients under the age of 18,
  • Patients who are unconscious, disoriented, or uncooperative,
  • Patients who cannot read or understand Turkish,
  • Patients with physical issues preventing the use of virtual reality glasses,
  • Patients with known neuropsychiatric disorders, diagnosed anxiety disorders, or those receiving antidepressant or anxiolytic treatment,
  • Patients with malignancy,
  • Patients who do not agree to participate or who do not sign the "Informed Consent Form" will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mersin University Faculty of Medicine

Mersin, Yenisehir, 33343, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

  • ahmet b KECECI, Research Assistant

    Mersin University faculty of medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ahmet B KECECI, Research Assistant

CONTACT

Emrah YEŞİL, specialist doctor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
researcher doctor

Study Record Dates

First Submitted

November 29, 2024

First Posted

December 10, 2024

Study Start

December 10, 2024

Primary Completion

March 1, 2025

Study Completion

April 1, 2025

Last Updated

December 10, 2024

Record last verified: 2024-12

Locations